Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics

Williams, Bryan; Lacy, Peter; Cruickshank, J.; Collier, David; Hughes, Alun D.; Stanton, Alice; Thom, Simon; Thurston, H.

doi:10.1161/circulationaha.108.785915

Cited by 97 publications

(52 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59 In the CAFE-LLA study, patients were also taking the antihypertensive drug, amlodipine. 60 In both studies, there were no significant differences in the variations in blood pressure during the follow-up period between the control and statin groups. These studies strongly support our view that statins modestly lower blood pressure in patients with high, but not normal, blood pressure, regardless of cholesterol level.…”

Section: Drugsmentioning

confidence: 77%

“…57 However, although statins may not improve blood pressure control in subjects with both hypercholesterolemia and controlled hypertension, statins markedly reduced the burden of cardiovascular disease. 59, 60 In clinical studies, combined therapy significantly reduced cholesterol levels and blood pressure, and increased adiponectin levels and thus improved endothelial dysfunction and insulin resistance. 56, 58 Statins also have many beneficial vascular effects on vasomotor function, inflammation, plaque stabilization, hemostasis, and smooth muscle cells.…”

Section: Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Atherosclerosis in Overweight/Obese Patients - In Need of Novel Multi-Targeted Approaches -

Lim

Després

Koh

2011

Circ J

View full text Add to dashboard Cite

Obesity has reached epidemic proportions and complications related to obesity contribute substantially to both healthcare costs and mortality. Obesity, particularly when accompanied by an excess of visceral/ectopic fat, is a major risk factor for diseases ranging from insulin resistance, type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular disease. The epidemic proportions reached by obesity has made these conditions a global problem in human health. Accordingly, preventive and/or therapeutic interventions should be considered in obese patients. Regular physical activity/exercise has numerous beneficial effects on the cardiometabolic risk profile and on the cardiovascular system. However, our current clinical environment is not designed to provide the regular support needed by patients to help them maintain over the long term their improved physical activity/nutritional habits. Because hypertension, dyslipidemia, hyperinsulinemia, and excess visceral adipose tissue are linked by complex reciprocal molecular interactions, it is logical to expect that targeting an interconnected pathway may provide multiple benefits. At this stage, combined therapy of statins or PPAR agonists and renin - angiotensinaldosterone system blockers to target multiple therapeutic pathways may optimally improve the cardiometabolic risk profile through both distinct and interrelated mechanisms. In the present article, we will discuss updated novel approaches, including potential multi-targeted intervention strategies, based on underlying pathophysiological processes. (Circ J 2011; 75: 1019 - 1027

show abstract

Section: Drugsmentioning

confidence: 77%

Section: Drugsmentioning

confidence: 99%

Prevention of Atherosclerosis in Overweight/Obese Patients - In Need of Novel Multi-Targeted Approaches -

Lim

Després

Koh

2011

Circ J

View full text Add to dashboard Cite

show abstract

“…At present, few vascular measurements have fully met these criteria. Nonetheless, several studies have demonstrated that central blood pressure 18) and FMD [19][20][21] might be useful in the therapeutic management of hypertension and cardiovascular disease.…”

Section: Therapeutic Treatmentmentioning

confidence: 99%

“…There is some evidence that β-blockers are less effective than other classes of antihypertensive drugs in central blood pressure lowering 18) . We performed a meta-analysis of trials that compared β-blockers with other classes of antihypertensive drugs in order to quantify to what extent the heart rate slowing effect of β-blockers accounts for the reduction of central augmentation index and central blood pressure and, in turn, the risk of stroke 22) .…”

Section: Therapeutic Treatmentmentioning

confidence: 99%

Research for Vascular Failure: Current Topics in China

Wang

2018

Vasc Fail

View full text Add to dashboard Cite

Abstract:"Vascular failure" is a new concept, which can be used interchangeably with "vascular dysfunction". It can be evaluated with several arterial properties, such as endothelial function, arterial stiffness, wave reflection, and intima-media thickness. The current Chinese hypertension guidelines recommend some of these vascular properties for risk assessment and stratification in the management of hypertension. However, none of these measurements are routine in the clinical setting in China, because of the lack of available devices and insufficient knowledge on the clinical efficacy of these vascular measurements. In order to improve the use of these vascular measurements in clinical practice, therapeutic research is required to prove reversibility of vascular failure by either pharmacological treatments or lifestyle modifications. Other research directions include identification of emerging risk factors, risk prediction and prevention with vascular measurements, and the development of newer, more accurate and efficient devices.

show abstract

“…Antihypertensive drugs have a different effect on compliance and central blood pressure, although the effect on peripheral blood pressure is equal [6,9].…”

Section: Introductionmentioning

confidence: 99%

The Pulse Pressure Amplitude as a Marker of Myocardial Infarction Risk

Atanasova¹

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Objective: In the present study, the importance of the pulse pressure amplitude as a marker of the risk of myocardial infarction (MI) is discussed. Methods:The 88 survivors of myocardial infarction were evaluated and a group of 106 healthy people is used as controls. The biomarkers: total cholesterol, HDL -cholesterol, serum triglycerides and LDL -cholesterol is measured with biochemical analyzer "Cobas Integra 400 (Roche)". ANOVA analysis is performed and multivariate analyses are conducted with multiple logistic regression methods. Results:The mean systolic blood pressure is significantly higher in MI participants. The relation between odds and pulse pressure amplitude, according to obtained models, indicates increasing of odds when the value of pulse pressure amplitude is greater. The p-value for overall model fit statistic is from 8.2173×10-5 to 0.0026 for different models and it is evidence that pulse pressure amplitude is a marker for MI risk. In the simplest model only pulse pressure amplitude is included as predictor variable whereas pulse pressure amplitude, sex and smoking are included in the most complex model. Results show that for a given pulse pressure amplitude odds of MI are significantly greater for men than for women. Expected increase of odds for the pulse pressure amplitude increase with 0.1 is obtained. Conclusions:The studies prove that pulse pressure amplitude is a marker of myocardial infarction risk. When the pulse pressure amplitude is used for risk level evaluation at least sex should be taken into account. Obtained results show that increased pulse pressure amplitude is greater risk for men than for women.

show abstract

Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics

Cited by 97 publications

References 32 publications

Prevention of Atherosclerosis in Overweight/Obese Patients - In Need of Novel Multi-Targeted Approaches -

Prevention of Atherosclerosis in Overweight/Obese Patients - In Need of Novel Multi-Targeted Approaches -

Research for Vascular Failure: Current Topics in China

The Pulse Pressure Amplitude as a Marker of Myocardial Infarction Risk

Contact Info

Product

Resources

About